C. Difficile Deaths Rise Dramatically

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Thursday, March 22, 2012
Follow Pharmacy_Times:
Deaths from infection with the gut bacteria quadrupled between 2000 and 2007, hitting the elderly particularly hard.


Annual deaths due to Clostridium difficile infection quadrupled between 2000 and 2007, to 14,000, the Centers for Disease Control (CDC) reports. More than 90% of patients who died from infection were aged 65 years or older, while just over half of those infected were aged 65 years or older. A significant portion of the increase is attributed to the emergence of drug-resistant strains of C. difficile.
 
C. difficile, which causes diarrhea and inflammation of the bowels, spreads via fecal contamination and tends to infect people whose native gut bacteria have been wiped out by antibiotics. The CDC report urges health officials to help fight its spread. “C. difficile harms patients just about everywhere medical care is given,” said CDC Director Thomas R. Frieden, MD, MPH. “Illness and death linked to this deadly disease do not have to happen.”
 
According to the report, 94% of cases are related to medical care in locations such as hospitals, doctor’s offices, clinics, and nursing homes. Pharmacists working in these environments should be aware of the potential for infection and look to implement practices to prevent the bacteria’s spread. C. difficile produces spores that can remain intact for months, so when an infected patient comes into contact with an area, it should be sterilized before other patients use it.

Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Related Articles
The FDA has cleared Roche’s cobas Strep A test for use by health care professionals in non-traditional settings, including pharmacies and physician offices.
Hospitals can now order Actavis’s ceftazidime-avibactam (Avycaz) to treat serious infections in adults.
Gilead Sciences is seeking FDA approval for emtricitabine/tenofovir alafenamide.
The FDA has granted 2 breakthrough therapy designations to grazoprevir/elbasvir.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$